Submission Review. The Party seeking to publish results hereunder (the “Publishing Party”) shall provide the other Party (the “Reviewing Party”) with a copy of such proposed abstract, manuscript, or presentation no less than sixty (60) days thirty (30) days in the case of abstracts) prior to its intended submission for publication. The Reviewing Party shall respond in writing promptly and in no event later than thirty (30) days (ten (10) Business Days in the case of abstracts) after receipt of the proposed material, with one or more of the following: (a) comments on the proposed material, which the Publishing Party shall consider in good faith; (b) a specific statement of concern, based upon the need to seek patent protection or to block publication if the Reviewing Party determines that the proposed disclosure is intellectual property that should be maintained as a trade secret to protect an Optioned Compound or any Research or Development activities conducted under this Agreement; or (c) an identification of the Reviewing Party’s Confidential Information that is contained in the material reviewed.
Appears in 2 contracts
Samples: Exclusive License Agreement (Felicitex Therapeutics Inc.), Research Collaboration and Option Agreement (Felicitex Therapeutics Inc.)
Submission Review. The Party seeking to publish results hereunder (the “Publishing Party”) shall provide the other Party (the “Reviewing Party”) with a copy of such proposed abstract, manuscript, or presentation no less than sixty [**] days (60) days thirty (30) [**] days in the case of abstracts) prior to its intended submission for publication. The Reviewing reviewing Party shall respond in writing promptly and in no event later than thirty (30) [**] days (ten (10) [**] Business Days in the case of abstracts) after receipt of the proposed material, with one or more of the following:
(a) comments on the proposed material, which the Publishing publishing Party shall consider in good faith;
(b) a specific statement of concern, based upon the need to seek patent protection or to block publication if the Reviewing reviewing Party determines that the proposed disclosure is intellectual property that should be maintained as a trade secret to protect an Optioned a Compound or any Research research or Development activities conducted under this Agreement; or
(c) an identification of the Reviewing reviewing Party’s Confidential Information that is contained in the material reviewed.
Appears in 2 contracts
Samples: Collaboration and License Agreement (Epizyme, Inc.), Collaboration and License Agreement (Epizyme, Inc.)
Submission Review. The Party seeking to publish results hereunder (the “Publishing publishing Party”) shall provide the other Party (the “Reviewing reviewing Party”) with a copy of such proposed abstract, manuscript, or presentation no less than sixty [**] days (60) days thirty (30) [**] days in the case of abstracts) prior to its intended submission for publication. The Reviewing reviewing Party shall respond in writing promptly and in no event later than thirty (30) [**] days (ten (10) [**] Business Days in the case of abstracts) after receipt of the proposed material, with one or more of the following:
(a) comments on the proposed material, which the Publishing publishing Party shall consider in good faith;
(b) a specific statement of concern, based upon the need to seek patent protection or to block publication if the Reviewing reviewing Party determines that the proposed disclosure is intellectual property that should be maintained as a trade secret to protect an Optioned a Compound or any Research or Development activities conducted under this Agreement; or
(c) an identification of the Reviewing reviewing Party’s Confidential Information that is contained in the material reviewed.
Appears in 2 contracts
Samples: Collaboration and License Agreement (Epizyme, Inc.), Collaboration and License Agreement (Epizyme, Inc.)
Submission Review. The Party seeking to publish results hereunder (the “Publishing Party”) shall provide the other Party (the “Reviewing Party”) with a copy of such proposed abstract, manuscript, or presentation no less than sixty (60) days thirty (30) days in the case of abstracts) prior to its intended submission for publication. The Reviewing Party shall respond in writing promptly and in no event later than thirty (30) days (ten (10) Business Days in the case of abstracts) after receipt of the proposed material, with one or more of the following:
(a) comments on the proposed material, which the Publishing Party shall consider in good faith;
(b) a specific statement of concern, based upon the need to seek patent protection or to block publication if the Reviewing Party determines that the proposed disclosure is intellectual property that should be maintained as a trade secret to protect an Optioned a Compound or any Research or Development activities conducted under this Agreement; or
(c) an identification of the Reviewing Party’s Confidential Information that is contained in the material reviewed.
Appears in 1 contract
Samples: Research Collaboration and Option Agreement (Felicitex Therapeutics Inc.)